Surfactant therapy in the acute respiratory distress syndrome

Acute Respiratory Distress Syndrome

Volumn , Issue , 2003, Pages 459-483

  Spragg, Roger G ^a   Lewis, James F ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34447618491     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (117)

1. Owen W. Dulce et Decorum Est. In: Anonymous Poems by Wilfred Owen with an Introduction by Siegfried Sassoon. London: Chatto and Windus, 1921.
2. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967; 2:319–323.
3. Petty TL, Reiss OK, Paul GW, Silvers GW, Elkins ND. Characteristics of pulmonary surfactant in adult respiratory distress syndrome associated with trauma and shock. Am Rev Respir Dis 1977; 115:531–536.
4. Hallman M, Spragg RG, Harrell JH, Moser KM, Gluck L. Evidence of lung surfactant abnormality in respiratory failure: study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982; 70:673–683.
5. Gregory TJ, Longmore WJ, Moxley MA, Whitsett JA, Reed CR, Fowler AAI, Hudson LD, Maunder RJ, Crim C, Hyers TM. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88:1976–1981.
6. Greene KE, Wright JR, Steinberg KP, Ruzinski JT, Caldwell E, Wong WB, Hull W, Whitsett JA, Akino T, Kuroki Y, Nagae H, Hudson LD, Martin TR. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999; 160:1843–1850.
7. Günther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, Temmesfeld B, Walmrath D, Morr H, Seeger W. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996; 153:176–184.
8. Veldhuizen RA, McCaig LA, Akino T, Lewis JF. Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152:1867–1871.
9. Robertson B, Van Golde LMG, Batenburg JJ, eds. Pulmonary Surfactant: From Molecular Biology to Clinical Practice. New York: Elsevier, 1992.
10. Gross NJ, Kellam M, Young J, Krishnasamy S, Dhand R. Separation of alveolar surfactant into subtypes. A comparison of methods. Am J Respir Crit Care Med 2000; 162:617–622.
11. Krishnasamy S, Gross NJ, Teng AL, Schultz RM, Dhand R. Lung “surfactant convertase” is a member of the carboxylesterase family. Biochem Biophys Res Commun 1997; 235:180–184.
12. Krishnasamy S, Teng AL, Dhand R, Schultz RM, Gross NJ. Molecular cloning, characterization, and differential expression pattern of mouse lung surfactant convertase. Am J Physiol 1998; 275:L969–L975.
13. Dhand R, Young J, Teng A, Krishnasamy S, Gross NJ. Is dipalmitoylphosphatidylcholine a substrate for convertase? Am J Physiol Lung Cell Mol Physiol 2000; 278:L19–L24.
14. Veldhuizen RA, Inchley K, Hearn SA, Lewis JF, Possmayer F. Degradation of surfactantassociated protein B (SP-B) during in vitro conversion of large to small surfactant aggregates. Biochem J 1993; 295:141–147.
15. Enhorning G. A pulsating bubble technique for evaluating pulmonary surfactant. J Appl Physiol 1977; 43:198–201.
16. Schurch S, Bachofen H, Possmayer F. Surface activity in situ, in vivo, and in the captive bubble surfactometer. Comp Biochem Physiol A Mol Integr Physiol 2001; 129:195–207.
17. Gilliard N, Heldt GP, Loredo J, Gasser H, Redl H, Merritt TA, Spragg RG. Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters surface tension properties. J Clin Invest 1994; 93:2608–2615.
18. Gupta M, Hernandez-Juviel JM, Waring AJ, Bruni R, Walther FJ. Comparison of functional efficacy of surfactant protein B analogues in lavaged rats. Eur Respir J 2000; 16:1129–1133.
19. Crouch E, Wright JR. Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol 2001; 63:521–554.
20. Borron P, McIntosh JC, Korfhagen TR, Whitsett JA, Taylor J, Wright JR. Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo. Am J Physiol Lung Cell Mol Physiol 2000; 278: L840–L847.
21. Kremlev SG, Phelps DS. Surfactant protein A stimulation of inflammatory cytokine and immunoglobulin production. Am J Physiol 1994; 267:L712–L719.
22. Korfhagen TR, LeVine AM, Whitsett JA. Surfactant protein A (SP-A) gene targeted mice. Biochim Biophys Acta 1998; 1408:296–302.
23. LeVine AM, Hartshorn K, Elliott J, Whitsett J, Korfhagen T. Absence of SP-A modulates innate and adaptive defense responses to pulmonary influenza infection. Am J Physiol Lung Cell Mol Physiol 2002; 282:L563–L572.
24. Linke MJ, Harris CE, Korfhagen TR, McCormack FX, Ashbaugh AD, Steele P, Whitsett JA, Walzer PD. Immunosuppressed surfactant protein A-deficient mice have increased susceptibility to Pneumocystis carinii infection. J Infect Dis 2001; 183:943–952.
25. Hawgood S, Poulain FR. The pulmonary collectins and surfactant metabolism. Annu Rev Physiol 2001; 63:495–519.
26. Wert SE, Yoshida M, LeVine AM, Ikegami M, Jones T, Ross GF, Fisher JH, Korfhagen TR, Whitsett JA. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci USA 2000; 97:5972–5977.
27. Clark JC, Wert SE, Bachurski CJ, Stahlman MT, Stripp BR, Weaver TE, Whitsett JA. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc Natl Acad Sci USA 1995; 92:7794–7798.
28. Glasser SW, Burhans MS, Korfhagen TR, Na CL, Sly PD, Ross GF, Ikegami M, Whitsett JA. Altered stability of pulmonary surfactant in SP-C-deficient mice. Proc Natl Acad Sci USA 2001; 98:6366–6371.
29. Ikegami M, Weaver TE, Conkright JJ, Sly PD, Ross GF, Whitsett JA, Glasser SW. Deficiency of SP-B reveals protective role of SP-C during oxygen lung injury. J Appl Physiol 2002; 92:519–526.
30. Schmidt R, Meier U, Yabut-Perez M, Walmrath D, Grimminger F, Seeger W, Gunther A. Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. Am J Respir Crit Care Med 2001; 163:95–100.
31. Raymondos K, Leuwer M, Haslam PL, Vangerow B, Ensink M, Tschorn H, Schurmann W, Husstedt H, Rueckoldt H, Piepenbrock S. Compositional, structural, and functional alterations in pulmonary surfactant in surgical patients after the early onset of systemic inflammatory response syndrome or sepsis. Crit Care Med 1999; 27:82–89.
32. Bersten AD, Hunt T, Nicholas TE, Doyle IR. Elevated plasma surfactant protein-B predicts development of acute respiratory distress syndrome in patients with acute respiratory failure. Am J Respir Crit Care Med 1998; 164: 648–652.
33. Doyle IR, Bersten AD, Nicholas TE. Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure. Am J Respir Crit Care Med 1997; 156:1217–1229.
34. Lin Z, Pearson C, Chinchilli V, Pietschmann SM, Luo J, Pison U, Floros J. Polymorphisms of human SP-A, SP-B, and SP-D genes: association of SP-B Thr131Ile with ARDS. Clin Genet 2000; 58:181–191.
35. Seeger W, Stöhr G, Wolf HRD, Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol 1985; 56:326–338.
36. Holm BA, Notter RH. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J Appl Physiol 1987; 63:1434–1442.
37. Seeger W, Günther A, Thede C. Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants. Am J Physiol 1992; 261:L286–L291.
38. Seeger W, Gunther A, Thede C. Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants. Am J Physiol 1992; 262:L286–L291.
39. Cockshutt AM, Weitz J, Possmayer F. Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 1990; 29:8424–8429.
40. Seeger W, Elssner A, Günther A, Kramer HJ, Kalinowski HO. Lung surfactant phospholipids associate with polymerizing fibrin: loss of surface activity [published erratum appears in Am J Respir Cell Mol Biol 1993 Oct; 9 (4):following 462]. Am J Respir Cell Mol Biol 1993; 9:213–220.
41. Günther A, Markart P, Kalinowski M, Ruppert C, Grimminger F, Seeger W. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity. Am J Respir Cell Mol Biol 1999; 21:738–745.
42. Schermuly RT, Gunther A, Ermert M, Ermert L, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Walmrath D. Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation. Am J Physiol Lung Cell Mol Physiol 2001; 280:L792–L800.
43. Holm BA, Wang Z, Notter RH. Multiple mechanisms of lung surfactant inhibition. Pediatr Res 1999; 46:85–93.
44. Lachmann B, Eijking EP, So KL, Gommers D. In vivo evaluation of the inhibitory capacity of human plasma on exogenous surfactant function. Intensive Care Med 1994; 20:6–11.
45. Veldhuizen RA, Marcou J, Yao LJ, McCaig L, Ito Y, Lewis JF. Alveolar surfactant aggregate conversion in ventilated normal and injured rabbits. Am J Physiol 1996; 270:L152–L158.
46. Ito Y, Veldhuizen RA, Yao LJ, McCaig LA, Bartlett AJ, Lewis JF. Ventilation strategies affect surfactant aggregate conversion in acute lung injury. Am J Respir Crit Care Med 1997; 155:493–499.
47. Kerr CL, Veldhuizen RA, Lewis JF. Effects of high-frequency oscillation on endogenous surfactant in an acute lung injury model. Am J Respir Crit Care Med 2001; 164:237–242.
48. Haddad IY, Ischiropoulos H, Holm BA, Beckman JS, Baker JR, Matalon S. Mechanisms of peroxynitrite-induced injury to pulmonary surfactants. Am J Physiol 1993; 265:L555–L564.
49. Haddad IY, Crow JP, Hu P, Ye Y, Beckman J, Matalon S. Concurrent generation of nitric oxide and superoxide damages surfactant protein A. Am J Physiol 1994; 267:L242–L249.
50. Gilliard N, Heldt GP, Loredo J, Gasser H, Redl H, Merritt TA, Spragg RG. Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters surface tension properties. J Clin Invest 1994; 93:2608–2615.
51. Seeger W, Lepper H, Hellmut RD, Neuhof H. Alteration of alveolar surfactant function after exposure to oxidative stress and to oxygenated and native arachidonic acid in vitro. Biochim Biophys Acta 1985; 835:58–67.
52. Liau DF, Yin NX, Huang J, Ryan SF. Effects of human polymorphonuclear leukocyte elastase upon surfactant proteins in vitro. Biochim Biophys Acta 1996; 1302:117–128.
53. Haddad IY, Crow JP, Hu P, Ye Y, Beckman J, Matalon S. Concurrent generation of nitric oxide and superoxide damages surfactant protein A. Am J Physiol 1994; 267:L242–L249.
54. Zhu S, Kachel DL, Martin WJ, Matalon S. Nitrated SP-A does not enhance adherence of Pneumocystis carinii to alveolar macrophages. Am J Physiol 1998; 275:L1031–L1039.
55. McGuire WW, Spragg RG, Cohen AB, Cochrane CG. Studies on the pathogenesis of the adult respiratory distress syndrome. J Clin Invest 1982; 69: 543–553.
56. Christner P, Fein A, Goldberg S, Lippmann M, Abrams W, Weinbaum G. Collagenase in the lower respiratory tract of patients with adult respiratory distress syndrome. Am Rev Respir Dis 1985; 131:690–695.
57. Pison U, Tam EK, Caughey GH, Hawgood S. Proteolytic inactivation of dog lung surfactantassociated proteins by neutrophil elastase. Biochim Biophys Acta 1989; 992:251–257.
58. Baker CS, Evans TW, Randle BJ, Haslam PL. Damage to surfactant-specific protein in acute respiratory distress syndrome. Lancet 1999; 353:1232–1237.
59. Hite RD, Seeds MC, Jacinto RB, Balasubramanian R, Waite M, Bass D. Hydrolysis of surfactant-associated phosphatidylcholine by mammalian secretory phospholipases A2. Am J Physiol 1998; 275:L740–L747.
60. Lewis JF, Tabor B, Ikegami M, Jobe AH, Joseph M, Absolom D. Lung function and surfactant distribution in saline-lavaged sheep given instilled vs. nebulized surfactant. J Appl Physiol 1993; 74:1256–1264.
61. Lewis JF, Goffin J, Yue P, McCaig LA, Bjarneson D, Veldhuizen RA. Evaluation of exogenous surfactant treatment strategies in an adult model of acute lung injury. J Appl Physiol 1996; 80:1156–1164.
62. Moya FR, Hoffman DR, Zhao B, Johnston JM. Platelet-activating factor in surfactant preparations. Lancet 1993; 341:858–860.
63. Häfner D, Beume R, Kilian U, Krasznai G, Lachmann B. Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS). Br J Pharmacol 1995; 115:451–458.
64. Amirkhanian JD, Bruni R, Waring AJ, Taeusch HW. Inhibition of mixtures of surfactant lipids and synthetic sequences of surfactant proteins SP-B and SP-C. Biochim Biophys Acta 1991; 1096:355–360.
65. Segerer H, van Gelder W, Angenent FW, van Woerkens LJ, Curstedt T, Obladen M, Lachmann B. Pulmonary distribution and efficacy of exogenous surfactant in lung-lavaged rabbits are influenced by the instillation technique. Pediatr Res 1993; 34:490–494.
66. Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, Moxley MA, Cai GZ, Hite RD, Smith RM, Hudson LD, Crim C, Newton P, Mitchell BR, Gold AJ. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155:1309–1315.
67. Walmrath D, Günther A, Ghofrani HA, Schermuly R, Schneider T, Grimminger F, Seeger W. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 1996; 154:57–62.
68. Lewis J, McCaig L, Hafner D, Spragg R, Veldhuizen R, Kerr C. Dosing and delivery of a recombinant surfactant in lung-injured adult sheep. Am J Respir Crit Care Med 1999; 159:741–747.
69. Schlosser RL, Veldman A, Fischer D, Funk B, Brand J, von L.V. Comparison of effects of perflubron and surfactant lung lavage on pulmonary gas exchange in a piglet model of meconium aspiration. Biol Neonate 2002; 81:126–131.
70. Lewis JF, McCaig L. Aerosolized versus instilled exogenous surfactant in a nonuniform pattern of lung injury. Am Rev Respir Dis 1993; 148:1187–1193.
71. Rebello CM, Jobe AH, Eisele JW, Ikegami M. Alveolar and tissue surfactant pool sizes in humans. Am J Respir Crit Care Med 1996; 154:625–628.
72. Gilliard N, Richman PM, Merritt TA, Spragg RG. Effect of volume and dose on the pulmonary distribution of exogenous surfactant administered to normal rabbits or to rabbits with oleic acid lung injury. Am Rev Respir Dis 1990; 141:743–747.
73. Spragg RG, Smith RM, Harris K, Lewis J, Häfner D, Germann P. Effect of recombinant SP-C surfactant in a porcine lavage model of acute lung injury. J Appl Physiol 1999; 88:674–681.
74. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants [Cochrane Review]. The Cochrane Library, Oxford: Update Software, 2002.
75. Novick RJ, MacDonald J, Veldhuizen RA, Wan F, Duplan J, Denning L, Possmayer F, Gilpin AA, Yao LJ, Bjarneson D, Lewis JF. Evaluation of surfactant treatment strategies after prolonged graft storage in lung transplantation. Am J Respir Crit Care Med 1996; 154:98–104.
76. Spragg RG, Lewis JF, Rathgeb F, Häfner D, Seeger W. Intratracheal instillation of rSP-C surfactant improves oxygenation in patients with ARDS. Am J Respir Crit Care Med. In press.
77. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301–1308.
78. Lachmann B. Surfactant replacement in acute respiratory failure: animal studies and first clinical trials. In: Lachmann B, ed. Surfactant Replacement Therapy. New York: Springer- Verlag, 1987:212–223.
79. Spragg RG, Gilliard N, Richman P, Smith RM, Hite RD, Pappert D, Robertson B, Curstedt T, Strayer D. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 1994; 105:195–202.
80. Weg JG, Balk RA, Tharratt RS, Jenkinson SG, Shah JB, Zaccardelli D, Horton J, Pattishall EN. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. J Am Med Assoc 1994; 272:1433–1438.
81. Anzueto A, Baughman R, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, Lemaire F, Long W, Zaccardelli DS, Pattishall EN. Aerosolized surfactants in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996; 334:1417–1421.
82. Haslam PL, Hughes DA, MacNaughton PD, Baker CS, Evans TW. Surfactant replacement therapy in late-stage adult respiratory distress syndrome. Lancet 1994; 343:1009–1011.
83. Günther A, Ruppert C, Schmidt R, Markart P, Grimminger F, Walmrath D, Seeger W. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res 2001; 2:353–364.
84. Seeger W, Spragg RG, Taut FJH, Häfner D, Lewis JF. Treatment with rSP-C surfactant reduces mortality in ARDS due to primary pulmonary events. Am J Respir Crit Care Med; 165:A219.
85. Kesecioglu J, Schultz MJ, Lundberg D, Lauven PM, Lachmann B. Treatment of acute lung injury (ALI/ARDS) with surfactant. Am J Respir Crit Care Med 2001; 165:A819.
86. Willson DF, Jiao JH, Bauman LA, Zaritsky A, Craft H, Dockery K, Conrad D, Dalton H. Calf’s lung surfactant extract in acute hypoxemic respiratory failure in children. Crit Care Med 1996; 24:1316–1322.
87. Lewis JF, Dhillon JS, Singh RN, Johnson CC, Frewen TC. Exogenous surfactant therapy for pediatric patients with the acute respiratory distress syndrome. Can Respir J 1997; 4:21–26.
88. Wiswell TE, Smith RM, Katz LB, Mastroianni L, Wong DY, Willms D, Heard S, Wilson M, Hite RD, Anzueto A, Revak SD, Cochrane CG. Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 160:1188–1195.
89. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 1999; 13:1455–1476.
90. Pison U, Seeger W, Buchhorn R, Joka T, Brand M, Obertacke U, Neuhof H, Schmit-Neuerburg KP. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 1989; 140:1033–1039.
91. Nakos G, Kitsiouli EI, Tsangaris I, Lekka ME. Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS. Alterations in leukocytes, proteins, PAF and surfactant components. Intensive Care Med 1998; 24:296–303.
92. Bersten AD, Doyle IR, Davidson KG, Barr HA, Nicholas TE, Kermeen F. Surfactant composition reflects lung overinflation and arterial oxygenation in patients with acute lung injury. Eur Respir J 1998; 12:301–308.
93. Berggren P, Lachmann B, Curstedt T, Grossmann G, Robertson B. Gas exchange and lung morphology after surfactant replacement in experimental adult respiratory distress syndrome induced by repeated lung lavage. Acta Anaesthesiol Scand 1986; 30:321–328.
94. Vazquez DAG, Lachmann RA, Gommers D, Verbrugge SJ, Haitsma J, Lachmann B. Treatment of ventilation-induced lung injury with exogenous surfactant. Intensive Care Med 2001; 27:559–565.
95. Eijking EP, Gommers D, So KL, Vergeer M, Lachmann B. Surfactant treatment of respiratory failure induced by hydrochloric acid aspiration in rats. Anesthesiology 1993; 78:1145–1151.
96. Strohmaier W, Redl H, Schlag G. Studies of the potential role of a semi-synthetic surfactant preparation in an experimental aspiration trauma in rabbits. Exp Lung Res 1990; 16:101–110.
97. van Daal GJ, Bos JA, Eijking EP, Gommers D, Hannappel E, Lachmann B. Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice. Am Rev Respir Dis 1992; 145:859–863.
98. van Daal GJ, So KL, Gommers D, Eijking EP, Fievez RB, Sprenger MJ, van Dam DW, Lachmann B. Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia. Anesth Analg 1991; 72:589–595.
99. Eijking EP, van Daal GJ, Tenbrinck R, Sluiters JF, Hannappel E, Erdmann W, Lachmann B. Improvement of pulmonary gas exchange after surfactant replacement in rats with Pneumocystis carinii pneumonia. Adv Exp Med Biol 1992; 316:293–298.
100. Berry D, Ikegami M, Jobe A. Respiratory distress and surfactant inhibition following vagotomy in rabbits. Am J Physiol 1986; 61:1741–1748.
101. Harris JD, Jackson FJ, Moxley MA, Longmore WJ. Effect of exogenous surfactant instillation on experimental acute lung injury. J Appl Physiol 1989; 66:1846–1851.
102. Anderson BM, Jackson FJ, Moxley MA, Longmore WJ. Effects on experimental acute lung injury 24 hours after exogenous surfactant instillation. Exp Lung Res 1992; 18:191–204.
103. Chen CM, Fang CL, Chang CH. Surfactant and corticosteroid effects on lung function in a rat model of acute lung injury. Crit Care Med 2001; 29:2169–2175.
104. Huang YC, Sane AC, Simonson SG, Fawcett TA, Moon RE, Fracica PJ, Menache MG, Piantadosi CA, Young SL. Artificial surfactant attenuates hyperoxic lung injury in primates. I Physiology and biochemistry. J Appl Physiol 1995; 78:1816–1822.
105. Loewen GM, Holm BA, Milanowski L, Wild LM, Notter RH, Matalon S. Alveolar hyperoxic injury in rabbits receiving exogenous surfactant. J Appl Physiol 1989; 66:1087–1092.
106. Hallman M, Merritt TA, Schneider H, Epstein BL, Mannino F, Edwards DK, Gluck L. Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome. Pediatrics 1983; 71:473–482.
107. Taeusch HW, Keough KM, Williams M, Slavin R, Steele E, Lee AS, Phelps D, Kariel N, Floros J, Avery ME. Characterization of bovine surfactant for infants with respiratory distress syndrome. Pediatrics 1986; 77:572–581.
108. Enhorning G, Shennan A, Possmayer F, Dunn M, Chen CP, Milligan J. Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial. Pediatrics 1985; 76:145–153.
109. Onrust SV, Dooley M, Goa KL. Calfactant: a review of its use in neonatal respiratory distress syndrome. Paediatr Drugs 1999; 1:219–243.
110. Robertson B, Curstedt T, Johansson J, Jornvall H, Kobayashi T. Structural and functional characterization of porcine surfactant isolated by liquid-gel chromatography. In: von Wichert P, Muller B, eds. Basic Research on Lung Surfactant. Progress in Respiration Research. Basel: Karger, 1990:237–246.
111. Disse B, Gortner L, Weller E, Eberhardt H, Ziegler H. Efficacy and standardization of SF-RI 1: a preparation from bovine lung surfactant. In: Lachmann B, ed. Surfactant Replacement Therapy in Neonatal and Adult Respiratory Distress Syndrome. Berlin: Springer, 1999:37–41.
112. Fujiwara T, Chida S, Watabe Y, Maeta H, Morita T, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980; 1:55–59.
113. Cochrane CG, Revak SD, Merritt TA, Heldt GP, Hallman M, Cunningham MD, Easa D, Pramanik A, Edwards DK, Alberts MS. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153:404–410.
114. Häfner D, Germann PG, Hauschke D. Effects of lung surfactant factor (LSF) treatment on gas exchange and histopathological changes in an animal model of adult respiratory distress syndrome (ARDS): comparison of recombinant LSF with bovine LSF. Pulm Pharmacol 1994; 7:319–332.
115. Morley CJ, Bangham AD, Miller N, Davis JA. Dry artificial lung surfactant and its effect on very premature babies. Lancet 1981; 1:64–68.
116. Durand DJ, Clyman RI, Heymann MA, Clements JA, Mauray F, Kitterman J, Ballard P. Effects of a protein-free, synthetic surfactant on survival and pulmonary function in preterm lambs. J Pediatr 1985; 107:775–780.
117. Spragg RG, Smith RM, Harris K, Lewis J, Häfner D, Germann P. Effect of recombinant SP-C surfactant in a porcine lavage model of acute lung injury. J Appl Physiol; 88:674–681.